APAC Pulmonary Fibrosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Drug, Type, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$999.7 MnPlaceholder estimate
Estimate 2025$1.09 Bn20.8% of the global market
Projected 2034$2.43 Bn 122.6%Adds $1.34 Bn over 9 forecast years
CAGR 2025–20349.3%Faster than 48% of 180 Pharmaceuticals markets here
Key players5
APAC is 20.82% of the global market.
Among regions, the largest is North America at $2.63 Bn.
Boehringer Ingelheim GmbH, Roche, United Therapeutics, Bristol-Myers Squibb, Pliant Therapeutics (see all)
Active clinical trials
89 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Pulmonary Fibrosis Treatment Market Analysis Executive Summary
Pulmonary fibrosis treatments slow scarring of the lungs, which makes breathing harder over time.
Key segments of the pulmonary Fibrosis Treatment market include drug (Nintedanib, Pirfenidone and Pipeline Therapies) and type (Idiopathic Pulmonary Fibrosis and Progressive Fibrosing ILD).
Asia Pacific Pulmonary Fibrosis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Pulmonary Fibrosis Treatment Market Dynamics
Market Growth Drivers
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the pulmonary Fibrosis Treatment market.
Opportunity
Earlier screening, new drug classes and home-based care give the pulmonary Fibrosis Treatment market room to grow.
Market Restraints
Late diagnosis, high prices of new medicines, limited specialist care and poor adherence hold back the pulmonary Fibrosis Treatment market.
Competitive Landscape for Pulmonary Fibrosis Treatment Market in APAC
The pulmonary Fibrosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Pulmonary Fibrosis Treatment Market in APAC
Pulmonary Fibrosis Treatment in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9], Thai FDA (Thailand)[10], BPOM (Indonesia)[11], DRAP (Pakistan)[12], MFDS (South Korea)[13] and Drug Administration of Vietnam (Vietnam)[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[15], basic medical insurance (China)[16], the Hospital Authority (Hong Kong)[17], Ayushman Bharat PM-JAY (India)[18], public health insurance (Japan)[19], subsidised public care (Malaysia)[20], Pharmac (New Zealand)[21], PhilHealth (Philippines)[22], MediShield Life (Singapore)[23], the Universal Coverage Scheme (Thailand)[24], JKN (BPJS Kesehatan) (Indonesia)[25], out of pocket and Sehat Sahulat (Pakistan)[26], National Health Insurance (South Korea)[27] and social health insurance (Vietnam)[28]. ClinicalTrials.gov lists 89 studies on Pulmonary Fibrosis Treatment that are recruiting, active or about to start in APAC.[29]
[29]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for pulmonary Fibrosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Drug
4.2 By Type
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Boehringer Ingelheim
7.2 Roche
7.3 United Therapeutics
7.4 Bristol Myers Squibb
7.5 Pliant Therapeutics
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The pulmonary Fibrosis Treatment market can be segmented based on various criteria, including drug, type and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: Drugs@FDA, US approvals each company holds for medicines on the market whose FDA label lists this use. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Pulmonary Fibrosis Treatment right now, from free public sources.
Clinical trials
89 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov.
Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Pulmonary Fibrosis Treatment market in Asia Pacific?
Placeholder estimate: about $1.09 Bn in 2025, rising to about $2.43 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Pulmonary Fibrosis Treatment market in Asia Pacific growing?
Placeholder estimate: about 9.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Pulmonary Fibrosis Treatment market report cover?
The report splits the market by drug (Nintedanib, Pirfenidone, Pipeline Therapies), type (Idiopathic Pulmonary Fibrosis, Progressive Fibrosing ILD) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Pulmonary Fibrosis Treatment market?
Key players include Boehringer Ingelheim GmbH, Roche, United Therapeutics, Bristol-Myers Squibb and Pliant Therapeutics.
What is driving the Pulmonary Fibrosis Treatment market?
Rising rates of chronic disease linked to diabetes, ageing, smoking and pollution, plus new treatments that slow disease, are driving the pulmonary Fibrosis Treatment market.
How many clinical trials on Pulmonary Fibrosis Treatment are running in Asia Pacific?
89 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Pulmonary Fibrosis Treatment?
PubMed lists 81 papers on Pulmonary Fibrosis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.